Share Price | Biofrontera, Inc. Stock Analysis & Recommendation

Q: How big is Biofrontera, Inc.?

Market Cap: As of Jun 18, Biofrontera, Inc. has a market capitalization of 5.97 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Biofrontera, Inc. reported net sales of 38.00 million and a net profit of -11.53 million.Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 4.43 million, while total assets were reported at 22.10 million.

Q: What does Biofrontera, Inc. do?

Overview: Biofrontera, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot: Most recent Net Sales: 9 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) Market-cap: USD 5.97 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: 2.85 Return on Equity: -1,716.40% Price to Book: 5.97 Contact Details: Registrar Address: Not available.

Q: Should I buy, sell or hold Biofrontera, Inc.?

Based on the current situation of Biofrontera, Inc., it would be advisable to hold your position rather than buy or sell at this time. The company is facing challenges, particularly with poor management efficiency indicated by a low return on equity (ROE) of 0%, which reflects its struggles to generate profits. While there have been some positive results recently, such as an increase in net profit and operating cash flow, the overall financial health remains concerning, especially with negative EBITDA. Additionally, the decrease in institutional investor participation suggests a lack of confidence in the company's future prospects, as these investors typically have more resources to analyze such fundamentals.Given these factors, holding your investment while monitoring the company's performance and market conditions would be a prudent approach.

Q: Is Biofrontera, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Biofrontera, Inc. has changed from bearish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating some positive momentum. However, the weekly RSI is bearish, suggesting potential weakness in the short term. The daily moving averages are mildly bullish, supporting the overall positive trend. Despite this mildly bullish stance, the stock has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -20.78% versus the S&P 500's 12.22%, and a one-year return of -33.06% compared to 17.14% for the index. Overall, the current technical stance is mildly bullish, but caution is warranted due to mixed signals from the RSI and other indicators.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

19.45 k

Shareholding (Sep 2025)

FII

11.04%

Held by 5 FIIs

DII

88.02%

Held by 1 DIIs

Promoter

0.00%

How big is Biofrontera, Inc.?

22-Jun-2025

As of Jun 18, Biofrontera, Inc. has a market capitalization of 5.97 million, with net sales of 38.00 million and a net profit of -11.53 million over the last four quarters. Shareholder's funds are 4.43 million, and total assets are 22.10 million as of Dec 24.

View full answer

What does Biofrontera, Inc. do?

22-Jun-2025

Biofrontera, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $9 million and a net loss of $4 million as of March 2025. It has a market cap of $5.97 million and key metrics indicating significant financial challenges.

View full answer

Should I buy, sell or hold Biofrontera, Inc.?

22-Jun-2025

Is Biofrontera, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Biofrontera, Inc. shows a mildly bullish trend with positive MACD indicators, but caution is advised due to a bearish RSI and significant underperformance compared to the S&P 500.

View full answer

Compare Biofrontera, Inc. with Similar Stocks

Eterna Therapeutics, Inc.Pasithea Therapeutics Corp.VYNE Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate -207.01% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -16.57

Flat results in Jun 25

Risky - Negative EBITDA

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 12 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.52

Return on Equity

710.58%

Price to Book

-4.51

Revenue and Profits:

Net Sales:

9 Million

(Quarterly Results - Jun 2025)

Net Profit:

-5 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-18.65%

6 Months

-16.63%

1 Year

-23.83%

2 Years

-8.92%

3 Years

-4.79%

4 Years

-99.05%

5 Years

0.0%

Biofrontera, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

53.36%

EBIT Growth (5y)

-207.01%

EBIT to Interest (avg)

-16.57

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

2.85

Sales to Capital Employed (avg)

12.13

Tax Ratio

0.17%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

23.97%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.67

EV to EBIT

-0.52

EV to EBITDA

-0.56

EV to Capital Employed

2.57

EV to Sales

0.22

PEG Ratio

Dividend Yield

ROCE (Latest)

-490.66%

ROE (Latest)

-1716.40%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 2 Schemes (0.94%)

Foreign Institutions

Held by 5 Foreign Institutions (11.04%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 15.38% vs 34.48% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -1,666.67% vs 96.94% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "9.00",
          "val2": "7.80",
          "chgp": "15.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.90",
          "val2": "-4.80",
          "chgp": "-2.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.60",
          "chgp": "-83.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.20",
          "val2": "5.40",
          "chgp": "-96.30%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.30",
          "val2": "-0.30",
          "chgp": "-1,666.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-562.50%",
          "val2": "-646.90%",
          "chgp": "8.44%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 9.38% vs 18.82% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 11.44% vs -3,250.00% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "37.30",
          "val2": "34.10",
          "chgp": "9.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.10",
          "val2": "-20.30",
          "chgp": "20.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.10",
          "val2": "0.60",
          "chgp": "250.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.50",
          "val2": "1.80",
          "chgp": "-16.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.80",
          "val2": "-20.10",
          "chgp": "11.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-461.10%",
          "val2": "-626.70%",
          "chgp": "16.56%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

9.00

7.80

15.38%

Operating Profit (PBDIT) excl Other Income

-4.90

-4.80

-2.08%

Interest

0.10

0.60

-83.33%

Exceptional Items

0.20

5.40

-96.30%

Consolidate Net Profit

-5.30

-0.30

-1,666.67%

Operating Profit Margin (Excl OI)

-562.50%

-646.90%

8.44%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 15.38% vs 34.48% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -1,666.67% vs 96.94% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

37.30

34.10

9.38%

Operating Profit (PBDIT) excl Other Income

-16.10

-20.30

20.69%

Interest

2.10

0.60

250.00%

Exceptional Items

1.50

1.80

-16.67%

Consolidate Net Profit

-17.80

-20.10

11.44%

Operating Profit Margin (Excl OI)

-461.10%

-626.70%

16.56%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 9.38% vs 18.82% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 11.44% vs -3,250.00% in Dec 2023

All Annual Results

Company CV

About Biofrontera, Inc.

Biofrontera, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Biofrontera, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Biofrontera, Inc.?

Watch in Real-Time

What does Biofrontera, Inc. do?

Should I buy, sell or hold Biofrontera, Inc.?

Is Biofrontera, Inc. technically bullish or bearish?

Compare Biofrontera, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Flat results in Jun 25

Risky - Negative EBITDA

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Biofrontera, Inc.

Company Coordinates